Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Meerbeeck, J., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H., Pinson, P., van Glabbeke, M., van Marck, E., Giaccone, G.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1996
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://ncbi.nlm.nih.gov/pubmed/8826866
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados